Studies in murine models with Usp22 deletion showed a decreased FoxP3 stability, reducing the immunosuppressive activity of Tregs and promoting a stronger antitumor response, suggesting its potential as a therapeutic target in cancers such as melanoma and colorectal cancer (78). This evidence concerns the gene FOXP3 and colorectal cancer.